Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial
Hospital Universitario 12 De Octubre · Fox Chase Cancer Center · +29 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
53
total citations
- FWCI
- 41.62
- Percentile
- 100%
- References
- 28
Citations per year
Authors
29Topics & keywords
Topics
Keywords
- Atezolizumab
- Medicine
- Carboplatin
- Oncology
- Internal medicine
- Clinical endpoint
- Etoposide
- Clinical trial
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.